Needham Maintains Buy on Revolution Medicines, Lowers Price Target to $61
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Ami Fadia maintains a Buy rating on Revolution Medicines (NASDAQ:RVMD) but lowers the price target from $62 to $61.
August 08, 2024 | 9:58 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Needham analyst Ami Fadia maintains a Buy rating on Revolution Medicines but lowers the price target from $62 to $61.
The maintained Buy rating suggests continued confidence in the stock, but the slight reduction in the price target may indicate some minor concerns or adjustments in valuation. Overall, the impact is neutral as the Buy rating is still in place.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100